For example, the identification of synthetic lethal interactions between BRCA1 or BRCA2 tumour suppressor genes and inhibition of the PARP1 DNA repair protein has driven the clinical development and approval for use of PARP inhibitors for the treatment of cancer [16]. The gene discussed is BRCA1; the disease is cancer.